|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
650501061
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»ö¢¦°ÅÀÇ Åõ¸íÇÑ ¾×ÀÌ µç Åõ¸íÇÑ À¯¸®¾ÚÇÃÁÖ»çÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
2mL ¡¿ 50¾ÚÇÃ |
| ÁÖ¼ººÐÄÚµå |
121330BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806505010603 |
| º¸°ü¹æ¹ý |
¹ÐºÀ¿ë±â, ½Ç¿Â(1¢¦30¡É) º¸°ü |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. ôÃßõÀÚ¿¡ ÀÇÇÑ µÎÅë
2. ¾ËÄÚ¿Ã ¶Ç´Â ¸ð¸£ÇÉ Áßµ¶¿¡ ÀÇÇÑ È£Èí¾ïÁ¦½Ã È£ÈíÈïºÐ º¸Á¶Á¦
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : º¥Á¶»ê³ªÆ®·ýÄ«ÆäÀÎÀ¸·Î¼ 1ȸ 100 ¡ 500 mg ±ÙÀ° ¶Ç´Â ÇÇÇÏÁÖ»çÇÑ´Ù. ±ä±ÞÇÒ °æ¿ì¿¡´Â Á¤¸ÆÁÖ»çÇÒ ¼ö ÀÖ´Ù.
Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| °æ°í |
¾ÚÇÃÁÖ»çÁ¦´Â ¿ë±â Àý´Ü½Ã À¯¸®ÆÄÆíÀÌ È¥ÀԵǾî, ºÎÀÛ¿ëÀ» ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î »ç¿ë ½Ã À¯¸®ÆÄÆí È¥ÀÔÀÌ ÃÖ¼ÒÈ µÉ ¼ö ÀÖµµ·Ï ½ÅÁßÇÏ°Ô Àý´Ü»ç¿ëÇϵÇ, ƯÈ÷ ¾î¸°ÀÌ, ³ë¾àÀÚ »ç¿ë ½Ã¿¡´Â °¢º°È÷ ÁÖÀÇÇÒ °Í(À¯¸®¾ÚÇÃÁÖ»çÁ¦¿¡ ÇÑÇÔ).
|
| ½ÅÁßÅõ¿© |
1) À§±Ë¾ç ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
2) ½ÉÀå¾Ö ȯÀÚ
3) ³ì³»Àå ȯÀÚ
4) ÀÌ ¾à¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼Òȱâ°è : ±¸¿ª, ¼³»ç µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼øÈ¯±â°è : ºó¸Æ, ½É°èÇ×Áø, ±â¿Ü¼öÃà µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ÁßÃ߽Űæ°è : ºÒ¸é, ÈïºÐ, ÁøÀü, ¾îÁö·³, µ¿°øÈ®´ë, ¼¶±¤¾ÏÁ¡(Scintillation-Scotoma), À̸í, ºÒ¾È µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ´« : ¸¸¼º ³ì³»ÀåÀ» ¾ÇȽÃŲ´Ù´Â º¸°í°¡ ÀÖ´Ù.
5) ±âŸ : ¹«·Â°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
ÀÌ ¾àÀ» °ú·®Åõ¿©ÇÒ °æ¿ì ¿ì¿ïÁõ ȯÀÚ¸¦ ´õ¿í ¿ì¿ïÇÏ°Ô ¸¸µé ¼ö ÀÖÀ¸¹Ç·Î 1ȸ ¿ë·®ÀÌ 1 gÀ» ³ÑÁö ¾Êµµ·Ï ÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ÀÜÆ¾°è ¾à¹°(¾Æ¹Ì³ëÇʸ°¼öȹ°, µðÇÁ·ÎÇʸ°, Å׿ÀÇʸ° µî) ¶Ç´Â ÁßÃ߽Űæ ÈïºÐÁ¦¿Í º´¿ëÅõ¿©½Ã º´¿ë¾à¹°ÀÇ ´ë»ç¿Í ¹è¼³À» Áö¿¬½ÃÄÑ °úµµÇÑ ÁßÃ߽Űæ ÈïºÐÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) MAO¾ïÁ¦Á¦¿Í º´¿ëÅõ¿©½Ã ºó¸Æ, Ç÷¾Ð»ó½Â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ½Ã¸ÞƼµò°ú º´¿ëÅõ¿©½Ã Ä«ÆäÀÎÀÇ ´ë»ç¿Í ¹è¼³À» Áö¿¬½ÃÄÑ °úµµÇÑ ÁßÃ߽Űæ°è ÈïºÐÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
Ä«ÆäÀÎÀº ŹÝÀ» Åë°úÇÏ¿© ¸ðÀ¯ÁßÀ¸·Î ½±°Ô ÀÌÇàµÇ¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º ¹× ¼öÀ¯ºÎ¿¡´Â Àå±â¿¬¿ëÀ» ÇÇÇÑ´Ù.
|
| ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© |
Ä«ÆäÀÎÀº ŹÝÀ» Åë°úÇÏ¿© ¸ðÀ¯ÁßÀ¸·Î ½±°Ô ÀÌÇàµÇ¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º ¹× ¼öÀ¯ºÎ¿¡´Â Àå±â¿¬¿ëÀ» ÇÇÇÑ´Ù.
|
| °í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿© |
ÀϹÝÀûÀ¸·Î °í·ÉÀÚ´Â »ý¸®±â´ÉÀÌ ÀúÇϵǾî ÀÖÀ¸¹Ç·Î °¨·®ÇÏ´Â µî ÁÖÀÇÇÑ´Ù. |
| Àû¿ë»óÀÇ ÁÖÀÇ |
1) Á¤¸ÆÁֻ縦 ÇÒ °æ¿ì¿¡´Â ÁÖ»ç¼Óµµ¸¦ ´À¸®°Ô ÇÑ´Ù.
2) ÁÖ»ç¹Ù´ÃÀº ÀÛÀº °ÍÀ» »ç¿ëÇÑ´Ù.
3) ±ÙÀ° ¶Ç´Â ÇÇÇÏ ÁÖ»ç ½Ã
(1) ½Å°æ ÁÖÇà ºÎÀ§¸¦ ÇÇÇϵµ·Ï ÁÖÀÇÇÑ´Ù.
(2) ¹Ýº¹ ÁÖ»çÇÏ´Â °æ¿ì¿¡´Â ÁÖ»ç ºÎÀ§¸¦ ¹Ù²Ù¾î ÁÂ¿ì ±³´ë·Î ÁÖ»çÇÑ´Ù.
(3) ÁÖ»ç ¹Ù´Ã¿¡ ÀÇÇØ °ÝÅëÀ» È£¼ÒÇϰųª Ç÷¾×ÀÇ ¿ª·ù°¡ ¹ß»ýÇÑ °æ¿ì¿¡´Â Áï½Ã ¹Ù´ÃÀ» »©°í ºÎÀ§¸¦ ¹Ù²Ù¾î ÁÖ»çÇÑ´Ù.
|
| °ú·®Åõ¿© ¹× óġ |
1) Áõ»ó : ¼Òȱâ Áõ»ó(¸Þ½º²¨¿ò, ±¸Åä µî), Ç÷°ü Áõ»ó(ºÎÁ¤¸Æ, Ç÷¾Ð »ó½Â µî), Á¤½Å ½Å°æ Áõ»ó(°æ·Ã, È¥¼ö µî), È£Èí±â Áõ»ó(È£ÈíÃËÁø, È£Èí¸¶ºñ µî) µîÀÇ ¾Çȸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
2) óġ : ¼ö¾× µî¿¡ ÀÇÇØ ÀÌ ¾àÀÇ ¹è¼³À» ÃËÁøÇÑ´Ù. ÈïºÐ »óÅ¿¡¼´Â ´ëÁõ¿ä¹ýÀ¸·Î µð¾ÆÁ¦ÆÊ, Æä³ë¹Ù¸£ºñÅ» µîÀÇ ÁßÃ߽Űæ¾ïÁ¦Á¦ Åõ¿©¸¦ °í·ÁÇϰí È£Èí°ü¸®¸¦ ½Ç½ÃÇÑ´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
¹ÐºÀ¿ë±â, ½Ç¿Â(1¢¦30¡É) º¸°ü |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Sodium benzoate¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Caffeine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Caffeine stimulates medullary, vagal, vasomotor, and respiratory centers, promoting bradycardia, vasoconstriction, and increased respiratory rate. This action was previously believed to be due primarily to increased intracellular cyclic 3¡Ç,5¡Ç-adenosine monophosphate (cyclic AMP) following inhibition of phosphodiesterase, the enzyme that degrades cyclic AMP. It is now thought that xanthines such as caffeine act as agonists at adenosine-receptors within the plasma membrane of virtually every cell. As adenosine acts as an autocoid, inhibiting the release of neurotransmitters from presynaptic sites but augmenting the actions of norepinephrine or angiotensin, antagonism of adenosine receptors promotes neurotransmitter release. This explains the stimulatory effects of caffeine. Blockade of the adenosine A1 receptor in the heart leads to the accelerated, pronounced "pounding" of the heart upon caffeine intake.
|
| Pharmacology |
Caffeine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Caffeine, a naturally occurring xanthine derivative like theobromine and the bronchodilator theophylline, is used as a CNS stimulant, mild diuretic, and respiratory stimulant (in neonates with apnea of prematurity). Often combined with analgesics or with ergot alkaloids, caffeine is used to treat migraine and other headache types. Over the counter, caffeine is available to treat drowsiness or mild water-weight gain.
|
| Absorption |
Caffeine¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed after oral or parenteral administration. The peak plasma level for caffeine range from 6-10mg/L and the mean time to reach peak concentration ranged from 30 minutes to 2 hours.
|
| Toxicity |
Caffeine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=127 mg/kg (orally in mice)
|
| Drug Interactions |
Caffeine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| SNP Á¤º¸ |
Name:Caffeine (DB00201)
Interacting Gene/Enzyme:Cytochrome P450 1A2 (Gene symbol = CYP1A2) Swissprot P05177
SNP(s):rs762551 (C allele)
Effect:Myocardial infarction
Reference(s):Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006 Mar 8;295(10):1135-41. [PubMed]
|
| Description |
Caffeine¿¡ ´ëÇÑ Description Á¤º¸ A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine&
|
| Dosage Form |
Caffeine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralElixir OralLiquid OralPill OralSolution OralSolution / drops OralSuppository RectalSuspension OralSyrup OralTablet OralTablet, extended release Oral
|
| Drug Category |
Caffeine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anorexigenic AgentsCentral Nervous System StimulantsPhosphodiesterase Inhibitors
|
| Smiles String Canonical |
Caffeine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
|
| Smiles String Isomeric |
Caffeine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
|
| InChI Identifier |
Caffeine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
|
| Chemical IUPAC Name |
Caffeine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3,7-trimethylpurine-2,6-dione
|
| Drug-Induced Toxicity Related Proteins |
CAFFEINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Metallothionein Drug:caffeine Toxicity:hepatotoxicity. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-08-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|